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PLASMID OPTIMIZATION AND THE LOCALIZATION OF THE BINDING 
SITE OF GPS2-UBC13  
AYESHA ABDULLAH 
ABSTRACT 
The GPS2 protein (G-protein pathway suppressor 2) is a product of the 
mammalian gps2 gene. It was originally identified and characterized in the context of G 
protein mitogen-activated protein kinase (MAPK) signaling pathways. Several studies 
have linked GPS2 with the inhibition of the ubiquitin conjugating enzyme UBC13. 
GPS2-mediated inhibition of UBC13 regulates several metabolic and inflammatory 
pathways. It has been shown that a lack of GPS2 is correlated with an increase in 
adiposity and inflammation due to the aberrant activity of UBC13 affected pathways. 
Therefore, understanding the relationship between UBC13 and GPS2 will provide further 
understanding of the molecular processes involved in adipose tissue levels, inflammation 
and downstream molecular responses. In this study, we attempt to determine the 
molecular determinants of GPS2 interaction with UBC13 by optimizing the protein 
expression protocol required to produce GPS2 protein expression in Escherichia coli in 
quantities viable for biochemical and structural assays. Our results indicate that 
optimization of the gps2 sequence is required for efficient GPS2 protein expression in E. 
coli cells. Thanks to this optimization we have been able to successfully express GPS2 
full length and several fragments, however, further optimization will be required for 
assessing GPS2-UBC13 molecular binding via in vitro binding assays. 
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INTRODUCTION 
Protein Ubiquitination: 
Ubiquitination is the addition of one or more ubiquitin molecules to a target 
protein. It is a very important biological process that affects a wide array of cellular 
processes through the covalent conjugation of ubiquitin to cellular proteins. 
Ubiquitination occurs by formation of an isopeptide bond between a lysine residue donor 
and the C-terminal carbonyl group at ubiquitin’s glycine 76 position. Three enzymes are 
required to make the isopeptide bond reaction. These enzymes are E1, a ubiquitin 
activating enzyme, E2, a ubiquitin-conjugating enzyme, and E3, the ubiquitin protein 
ligase. The E1 enzyme forms an initial thioester bond with the carboxyl terminus of the 
ubiquitin molecule. This occurs in an ATP-dependent reaction. After the thioester bond 
forms, the E2 transfers the ubiquitin to its own active site cysteine. The isopeptide bond 
then forms as a lysine residue of the substrate protein attacks the E2 bond ubiquitin. 
Lastly and simultaneously, this attack requires an E3 enzyme which binds the E2 
ubiquitin thioester and the protein being ubiquitinated (Hershko and Ciechanover, 1998). 
Ubiquitination can occur through the addition of a single ubiquitin molecule 
(mono-ubiquitination), the addition of several ubiquitin monomers (multiple mono-
ubiquitination), or the addition of a polymeric chain of ubiquitin molecules (poly-
ubiquitination). Such polyubiquitin chains are connected through a covalent bond 
between the C-terminus of one ubiquitin and one of the seven lysine side chains of the 
next ubiquitin (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, or Lys63) or the amino-
terminal methionine (M1) of the next ubiquitin (Chau et al., 1989; Eddins M. et al., 2006; 
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Meinnel T. et al., 2006). Polyubiquitin chains with different lysine linkages are usually 
referred to by the position of the ubiquitin Lys used for branching, and often have distinct 
biological roles (VanDemark A. et al. 2001). Best studied are chains with Lys-48 
linkages that are known to signal proteins for degradation by the 26S proteasome. 
Ubiquitination pathways that do not tag proteins for degradation, however, also exist. 
Chains with Lys-63 linkages, for example, do not signal degradation. This ubiquitination 
pathway has been linked to post replicative DNA repair after UV damage, IKK 
inflammation pathways, general translational regulation, as well as some types of 
ubiquitin-dependent endocytosis (VanDemark A. et al. 2001; Eddins M. et al., 2006).  
 
G-Protein Pathway Suppressor 2 (GPS2): 
GPS2 (G-protein pathway suppressor 2) is a 36kDa ubiquitously expressed 
protein. The protein was initially studied in the context of G protein-mitogen-activated 
protein kinase (MAPK) signal pathways (Spain et al., 1996). Then it was identified as a 
transcriptional cofactor that interacts with NCoR/SMRT corepressor complex in gene 
repression and interacts with nuclear receptors and other transcription factor in gene 
activation (Zhang et al., 2002; Sanyal et al., 2007; Jakobsson et al., 2009; Cardamone et 
al., 2018). More recently, non-genomic functions of GPS2 in the cytosol have been 
reported by our lab. In particular,  it was found that GPS2 in adipocytes is a negative 
regulator of AKT activation, required for restricting its activity and downstream signaling 
activity at low insulin levels (Cenderquist et. al, 2016). In mice, upon GPS2 deletion, the 
PI3K/AKT pathway is found constitutively activated, lipid metabolism disrupted, and 
3  
adiposity is increased (Cenderquist et al., 2016). In cytoplasm, GPS2 inhibits of the 
enzymatic activity of TRAF/UBC13. The downstream molecular response is the 
inhibition of inflammatory TNF-α genes (Cardamone et al., 2012). Our lab has also 
identified GPS2 as an important protein in mitochondrial retrograde signaling as well as a 
transcriptional activator of nuclear encoded mitochondrial genes for mammals 
(Cardamone et al., 2018). To this end, GPS2 recruitment to its target genes promotes 
histone H3K9 demethylation and RNA POL2 activation via UBC13 inhibition. Notably, 
the same strategy is also important for the activation of the nuclear stress response to 
mitochondrial depolarization (Cardamone et al., 2018).  
 
GPS2 as a regulator of protein ubiquitination: 
Overall, these previous studies indicate that GPS2 is an important protein to study 
and that determining its mechanisms of action is important to understand how to 
modulate its functions as a regulator of inflammation, lipid metabolism and 
mitochondrion homeostasis (Spain et al., 1996; Bi H. et al., 2014). As mentioned, our 
lab’s previous study found GPS2 can regulate insulin signal and pro-inflammatory 
pathways via inhibition of the UBC13 activity (Cardamone et al., 2012, 2014; Cederquist 
et al., 2016; Lentucci et al., 2016). Specifically, GPS2 acts as a negative regulator of 
inflammation by inhibiting the pro-inflammatory TNF-α pathway via inhibition of 
UBE2N/UBC13-mediated ubiquitination of RIP1 (Cardamone at al., 2012). Similarly, in 
adipocytes, GPS2 negatively regulates activation of insulin signaling by means of the 
inhibition of UBE2N/UBC13-mediated ubiquitination of AKT (Cederquist et al., 2016). 
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In the nucleus as well, GPS2-mediated inhibition of UBC13 activity appear to regulate 
chromatin remodeling, and thus expression, of target genes via stabilization of a histone 
demethylase (Cardamone et al., 2018) . 
UBE2N, in eukaryotes, or UBC13 in prokaryotes, is the main ubiquitin-
conjugating enzyme (E2) that conjugates the synthesis of lysine 63-linked ubiquitin 
chains (Eddins et al., 2006). GPS2 inhibits Lys-63-linked ubiquitination (Eddins et al., 
2006). GPS2 performs its regulatory activities by preventing the synthesis of Lys-63-
poly-ubiquitin chains via direct interaction with UBC13 (Lentucci et al., 2016), however 
the mechanistic details of this inhibition are not known.  
 
UBC13 structural information and mechanism of action: 
A special type of E2, a UEV (ubiquitin E2 variant protein),  acts as a subunit E2 
in the assembly of K63-linked poly-ubiquitin chains. UEVs function directly with 
UBC13 in the assembly of K63 chains (VanDemark et al., 2001). In one study, a 
fundamental eukaryotic UEV protein, the Mms2 protein in yeast (its related and 
structurally similar human UEV protein is UEV1a), is used to show the binding and 
structural interaction between UEVs and UBC13 that lead to K63 polyubiquitin chains 
(VanDemark et al., 2001). The study shows that Mms2 and UBC13 form a T-shaped 
dimer that allows for the binding of ubiquitin’s glycine 76 and the subsequent forming of 
the isopeptide bond (VanDemark et al., 2001). Furthermore, ubiquitin sequencing shows 
that there are two glycine residues in succession (at positions 75 and 76) at the binding 
site during the bonding of ubiquitin to UBC13. Thus, in the process of synthesizing Lys-
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63-linked polyubiquitin chains, donor ubiquitin’s glycine attaches to UBC13 at its active 
site to form UEV-E3-Ubiquitin. For our study, it will be important to note that the protein 
GPS2, which also binds to UBC13, also has two glycine residues, in sequence, at two 
particular locations on its amino acid primary sequence.  
 
Project Outline and Goals: 
Many studies have suggested GPS2 and UBC13 as a potential therapeutic targets 
for intervention in various different cancers, the alleviation of anti-cancer drug resistance, 
chronic inflammation – especially that associated with obesity – and some viral infections 
(Fan R. et al., 2016; Huttlin E. et al., 2017; de Chassey B. et al., 2008). Further 
characterization of the role of UBC13 and improved mechanistic understanding of its 
inhibition by GPS2 are essential in order to determine the usefulness of such 
interventions and to design specific approaches. 
The long-term goal of the present project is to study the GPS2-UBC13 molecular 
interaction in order to identify GPS2’s mechanism of inhibition. In order to dissect the 
GPS2-UBC13 interaction, we planned to use in-vitro binding assay. Firstly, a sufficient 
amount of each protein must be gathered in order to perform binding and functional 
interaction assays. Additionally, in order to localize the minimal binding surface between 
these two proteins, we must perform binding assays between various fragments of GPS2 
and UBC13. Lastly, we can use site-specific mutagenesis to alter specific residues that 
may be important for the binding or inhibitory activity and test their relevance. In 
particular, as mentioned above, it is known that UBC13 binds ubiquitin at the C-terminal 
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GG site. Because the protein sequence of GPS2 also includes two separate sites with 
sequential GGs, the specific hypothesis we would like to test is that one of the GGs sites 
on GPS2 are involved in the binding of GPS2 to UBC13.  
Overall, the constructs/mutations we set out to test include: the full length wild 
type variation of UBC13 and GPS2, three variations of the full length GPS2 with a 
mutation of both of the GG sites (1st GG mutation, 2nd GG mutation, as well as double 
mutation), fragments of GPS2 that include amino acids 1-212 (GPS2 1-212), a fragment 
that includes amino acids one through GPS2’s first GG (GPS2-1st GG), a fragment that 
includes amino acids one through GPS2’s second GG (GPS2-2nd GG), a fragment that 
includes the first 99 amino acids of GPS2 (GPS2 1-99), a fragment that includes the first 
133 amino acids of GPS2 (GPS2 1-133), and lastly a fragment that includes the last 115 
amino acids of GPS2 (GPS2 212-327). GPS2 fragments including amino acids 1-99 and 
1-133 were chosen to test N-terminal sufficiency, while GPS2 212-327 was chosen to test 
C-terminal sufficiency. GPS2 1-133, GPS2 1-99, GPS2 212-327, and GPS2 1-212 were 
chosen as positive controls from previous mapping results. As we hypothesize that the 
first or second GG in GPS2’s sequence is required in binding, we also planned to 
generate full-length GPS2 containing mutations at these sites. These GPS2 variations will 
be central to the long-term goal of determining whether the binding of GPS2 and UBC13 
require either of the GG sites. 
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Specific Aims: 
In order to investigate the required domain/site on GPS2 binding to UBC13, our goals 
were: 
(1)  Construct plasmids expressing GST-tagged GPS2 full length or deletions; 
(2)  Test the expression of targeted proteins in E. Coli; 
(3)  Purify proteins and test for expression; 
(4)  Mutagenesis of either wild type or optimized full length GPS2 at each GG and 
both GG sites; 
(5)  Prepare TnT Quick Coupled Transcription/Translation and begin performing 
binding assays 
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MATERIALS AND METHODS 
 
Transformation, Culturing, and Induction of E. Coli cells: 
In preparation for protein purification, BL21 competent cells (BioLabs) previously 
stored in a -80°C refrigerator were used to transform plasmids containing GPS2 or GPS2 
fragment plasmids. After thawing on ice, one to two microliters of plasmid was 
transferred into the competent cells vial. After incubating on ice for thirty minutes, the 
vial was placed in a 42°C water bath for exactly thirty seconds. The vial was removed 
and placed immediately on ice for two minutes. After two minutes, one milliliter of LB 
medium was added to the vial and the vial was then place in incubation at 37°C and 
shaken for one hour. Approximately fifty microliters of the media and cells were place 
onto a plate with vector-related resistance for easy transformation cells (for difficult 
transformation cells, i.e. initial plasmid transformation, media was spun down, ninety 
percent of supernatant removed, and then cells were resuspended in remaining one 
hundred microliters and spread on plate). Plates were then incubated at 37°C overnight. 
The following morning, nine to twelve colonies were replated and incubated again for 
five to eight hours. 
For cell culturing and induction, a colony sample was added to five milliliters of LB 
medium with related resistance and cultured overnight. Approximately 12 hours later, 
one to five milliliter of the culture was removed and diluted with LB medium in a one to 
one hundred ratio in a five hundred milliliter flask. Cultures were incubated for one to 
two hours and shaken at 37°C until concentration reached 0.3-0.5 OD600. IPTG (Fisher 
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Bioreagents) was then added to the cultures, diluted to one to one thousand from a 0.5M 
stock. Induced cultures were then incubated at 25-30°C for three to four hours. 
 
Protein Purification and western blotting:  
To extract whole cell lysates, bacteria cells were harvested and spun down for 
15min at 3000 rpm (4C). Cell pellet was resuspended in cold lysis buffer (50mM Tris 
Hcl, pH7.5, 400mM NaCl, 10% glycerol, 0.1% NP40, 1mM EDTA, 1mM DTT, 0.1mM 
PMSF and protease inhibitor mix (Roche Diagnostics))  Pellets were kept on ice to 
preserve proteins during the entire process. In order to lyse the cells fully, pellets 
suspended in lysis buffer were separated into sonicator tubes and sonicated for six 
minutes at 60% amplitude for 30 seconds work time and 30 second rest and cool time. 
Samples were then spun down at max speed for 10 minutes at 4°C. Supernatant was 
taken as whole cell lysates. Concentration of the protein extracts were 
measured using the Quick Start™ Bradford 1X Dye Reagent per manufacturer’s protocol 
(Bio-Rad) and the NanoDrop™2000. Glutathione Sepharose 4B beads (Thermo Fisher) 
were washed three times with lysis buffer, then added to the whole cell lysates. The 
Glutathione Sepharose 4B beads-sample mixture was then place in 4°C to rotate and 
incubate overnight.  
Approximately 12 hours later, the Glutathione Sepharose 4B beads-sample was 
spun down at approximately 600 rpm in 4°C. The supernatant was removed and labelled 
as flow through. Beads were washed with wash buffer (PBS, 300mM NaCl) for three 
times. All samples were boiled with NuPAGE LDS Sample Buffer-4X (Life 
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Technologies) and DTT at 100°C for 10 minutes  Samples were then loaded into either a 
stain free 10% gel (if silver stain intended) or a stained 10% gel (Bio-Rad Mini-
PROTEAN® TGXTM). A Bio-Rad Precision Plus Protein™ Dual Color Standards was 
used for the ladder and gels were run using Boston BioProducts 1x Tris-Glycine-SDS 
Running Buffer. Proteins were then transferred onto PVDF membranes (EMD Millipore), 
followed by standardized western blotting protocol. Chemiluminescent western blot 
detection was performed using Clarity™ Western ECL Substrate and ChemiDoc™XRS+ 
with Image Lab software per manufacturer’s protocol (Bio-Rad). GST primary antibody 
(Santa Cruz Biotechnology) were used in this study.  
 
PCR reaction: 
For plasmid creation, primers were diluted with distilled water to 100uM. Primers 
were then diluted to 10uM in 1.5mL tubes in preparation for individual PCR reaction 
experiments. Each PCR reaction formula were made to contain 500ug plasmid template, 
1x high fidelity PCR buffer, 200nM dNTP mixture, 2mM MgSO4, 1U Taq Polymerase 
(5u/uL),40nM forward primer as well as 40nM reverse primer, and nuclease free water to 
final 50ul (Fisher Bioreagents). Typical PCR protocol was followed at temp 37 °C 
Celsius. PCR products were cleaned with a Qiagen QIAquick PCR Purification kit. PCR 
Products were run on DNA gel electrophoresis to test for correct base pair length. Gels 
were 10% agarose in 1x TBE. A 1:1000 allotment of Denville Scientific Greenglo DNA 
Dye was added to the gel. Fisher Scientific exACT Gene 1kb Plus DNA was used as a 
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ladder and 1x TBE was used to run the gel. The correct sized PCR products were 
extracted using Qiagen QIAquick Gel Extraction Kit. 
 
PCR Product Digestion and Ligation Solutions:  
In order to construct plasmid expressing target genes, we digested purified DNA 
fragment and expressing vector using same restriction endonucleases to generate the 
adhesive ends. The restriction endonucleases used in our study are BamHI and EcoRI 
(NEB). For ligation reaction, T4 ligase (BioLabs) were used as mentioned in manufacture 
introduction.  
 
Silver Stain Protocol: 
Silver staining was performed in order to determine protein purification levels 
down to the nanogram level. Thermo Fisher Scientific Pierce Silver Stain Kit was used 
for silver staining. In order prepare for silver staining, a fixing solution, ethanol solution, 
sensitizer working solution, developer working solution, and a stop solution were made. 
25ml of each solution was created for each silver stain. The fixing solution contained a 
30% pure ethanol and 10% acetic acid. The ethanol solution contained 10% pure ethanol 
in water. The sensitizer working solution contained 25ul sensitizer in 25ml water. The 
developer working solution contained 0.5mL of enhancer in 25ml developer. The stop 
solution contained 5% acetic acid in water. 
All steps were performed in a single clean staining plastic tray with constant 
gentle shaking. Gels were handed with clean gloved hands to manipulate the gel to 
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reduce contamination. Fixing, ethanol, and stop solutions were prepared in advance. 
Other solutions were prepared immediately before use. 
First, the gel was washed in pure water for 5 minutes. The water was then 
replaced and the gel was washed for another 5 minutes. The gel was then fixed in the 
fixing solution for 15 minutes. The fixing solution was replaced and the gel was fix for 
another15 minutes. The gel was then washed in the ethanol solution for 5 minutes. The 
solution was replaced and the gel was washed for another 5 minutes. The gel was then 
washed in pure water for 5 minutes, the water was replaced and the gel was washed for 
another 5 minutes. The sensitizer working solution was then prepared by mixing one-part 
Silver Stain Sensitizer with five hundred parts pure water. The gel was then incubated in 
the sensitizer working solution for exactly 1 minute, then washed with two changes of 
pure water for 1 minute each. The stain working solution was then prepared by mixing 
one-part Silver Stain Enhancer with fifty parts Silver Stain. The gel was then incubated in 
the stain working solution for 30 minutes. The developer working solution was then 
prepared by mixing one-part Silver Stain Enhancer with fifty parts Silver Stain 
Developer. The stop solution was also kept ready at hand at this time. The gel was 
quickly washed with two changes of ultrapure water for 20 seconds each. Immediately 
following the wash, the developer working solution was added and the gel was incubated 
until protein bands appear. This took roughly one minute. At that time, the developer was 
removed and the stop solution was immediately added. The gel was incubated for 10 
minutes, the stop solution removed, and more stop solution added. The gel remained in 
the stop solution for 10 minutes and then placed in pure water for viewing. 
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Mutagenesis: 
Site-Directed Mutagenesis Kit from Agilent Technologies was used to create 
mutations. A control and sample solution were both prepared. Using the Agilent kit, a 
50ul solution total in a PCR tube, 5ul of 10x buffer, 1.2 ul of the kit’s prepared primers, 
1ul of the kit’s dNTP, 0.5 ul of the kit’s DNA, 3ul of the kit’s QuikSolution, 38ul of 
nuclease free water, and 1ul of the kit’s PfuTurbo DNA polymerase (2.5u/uL) were 
mixed into a control PCR solution. For the desired product solution, 5ul of 10x reaction 
buffer, 10ul of GPS2 (GPS2 or 2nd GG mutation) DNA template, 125ng of the forward 
primer as well as 125ng of the reverse primer. 1ul of dNTP nucleotides, 3ul of 
QuikSolution and 1ul of Pfu DNA polymerase were added to solution and nuclease free 
water was added to make a final volume of 50ul. The reaction was cycled using the 
below parameters with an eighteen-cycle limit. Cycle each reaction using the cycling 
parameters outlines 
Segment Cycles Temperature Time 
1 1 95°C 1min 
2 18 95°C 
60°C 
68°C 
50 sec 
50 sec 
1min/kb of plasmid 
length 
3 1 68°C 7 min 
Figure 1: Mutagenesis cycling parameters 
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Following temp cycling, the reaction tubes were placed on ice for two minutes to 
cool reactions to less than 37°C. Dpn I from the Mutagenesis kit was then added to each 
solution for digestion of parent DNA. After incubation at 37°C for 1 hour, the 1ul of the 
DNA was then transformed to competent cells (BioLabs). 
 
Mini and Midi Plasmid Purifications: 
A Qiagen Hispeed Plasmid Midi Kit was used to purify plasmid products 
following PCR creation and transformation. For midi purification, 50ml of LB media 
with 1mM ampiciline was added to a culturing tube. Desired bacteria was added to the 
tube and it was incubated overnight at 37°C. For mini purification, 5ml of LB media and 
desired bacteria was cultured. For each midi and mini, culture was placed in 1.5mL tubes. 
The tubes were then spun at max speed in centrifuge to get a pellet and supernatant was 
removed. The pellet was then resuspended in P1 buffer and incubated at room 
temperature for 5 minutes. P2 buffer was added to the solution and the solution was 
incubated at room temperature for 5 minutes. P3 buffer was then added to the solution 
and it was again incubated at room temperature for 5 minutes. The solution was then spun 
down at max speed in a centrifuge held at 4°C for 10 minutes. The supernatant was then 
removed and added to new tubes. Isopropanol was then added to the supernatant at a 0.7x 
ratio. The tube was then vortexed for 10 seconds to mix the isopropanol and then 
incubated at 4°C for 10 minutes to aid precipitation of DNA. Tubes were then spun down 
by centrifuge for 15 minutes at max speed, at 4°C. The isopropanol was removed and the 
DNA pellet was washed with 500 ul 70% ethanol. The tubes were then spun again at max 
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speed for 5 minutes at 4°C. Ethanol was removed and DNA was air dried for 10 minutes 
and then resuspended in 30ul nuclease free water. 
 
In-vitro transcriptional and translational reaction (TnT): 
In-vitro transcriptional and translational reaction was performed by TnT Quick 
Master Mix (Promega) following the manufacture introduction. Flag-tagged GPS2 
fragment 1-212 and myc-tagged Ubc13 were formulated by TnT reaction. TnT Quick 
Master Mix was rapidly thawed by hand-warming and place on ice after removing from -
80°C storage. Plasmid DNA used for TnT reaction and Methionine were thawed at room 
temp and stored on ice. The TnT reaction was including 1x TnT Quick Master Mix, 1ug 
plasmid DNA and 20nM methionine. The reaction was incubated at 37°C for 1hour. 
Generated proteins were analyzed by western blot. Myc antibody (Santa Cruz 
Biotechnology) and Flag antibody (Santa Cruz Biotechnology) were used for standard 
western blot analysis. 
 
In-vitro binding Assay: 
Binding buffer (20mM Tris, pH8.0, 125mM NaCl, 10% glycerol, 0.1% NP40, 
0.5mM DTT and PIC) was used to perform binding assays with products of the TnT 
reaction and GPS2 protein purification products.  
First, Glutathione Sepharose 4B beads were washed with binding buffer twice for 
10 minutes each. Beads were then resuspended with 300ul binding buffer.5ul of the TnT 
reaction were then added to the prewashed beads. The solution was place in 4°C to rotate 
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for 1 hour. The beads were then washed with binding buffer three times with ten-minute 
incubation each time. SDS loading buffer was then added to the samples. Sampled were 
boiled at 100C for 10 minutes and loaded into a stain free gel. Results were analyzed by 
western blot with the same products used to analyze TnT western results. 
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RESULTS 
 
 
GPS2 Plasmids and Protein Expression: 
 
The expression of proteins is a very important step in determining the structure 
and the binding of proteins to its partners. Often, protein expression is conducted using E. 
coli. As there is overlap and redundancy in the genetic code for protein expression 
between all living organisms, expressing proteins endogenous to eukaryotes can be done 
in bacteria. However, differences in coding and in protein length can affect the efficiency 
of protein expression. While all organisms have molecular mechanisms for ubiquitination 
and the enzymes responsible for Lys63 polyubiquitin chains are homologous in eukaryote 
organisms and bacteria, the specific genetic sequence encoding for the UBC13 protein 
sequence varies between eukaryotes and prokaryotes. Because this enzyme is 
homologous in both eukaryotes and prokaryotes, expression of the endogenous eukaryote 
protein in E. coli does not present complications. Moreover, because the protein is small, 
the smaller bacterial cell does not have a problem synthesizing UBC13. GPS2 is 
endogenous to mammals but not to bacterial cells, however. Additionally, GPS2 is a 
larger protein comparatively to UBC13 (37kD and 23kD) respectively). Thus, GPS2 
expression in E. coli and many of its larger fragments, in order to be synthesized in E. 
coli, require optimization. 
 Sequence optimization is the process of changing the DNA coding for specific 
amino acids from that preferred by eukaryotes to that preferred by prokaryotes, 
specifically here E. coli. A major goal of this project is the development of an optimized 
plasmid for the successful purification of GPS2 and various fragments of GPS2. The 
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development of an optimized plasmid is crucial to purifying GPS2 and various fragments 
in order to acquire sufficient protein expression by means of protein purification methods 
(Nieuwkoop T. et al. 2019). Proteins gathered from protein purification are subsequently 
used to perform binding assays to determine the molecular binding site of GPS2 and 
UBC13. Thus, the goals of this project are twofold: the creation of plasmids capable of 
successful (>~50ng) GPS2 (and fragments) purifications and the determination of the 
binding site of GPS2 and UBC13.  
 
This project begins with the determination of which GPS2 protein fragments 
(GPS2, GPS2-1st GG, GPS2-2nd GG, GPS2 1-212, GPS2 1-99, GPS2 1-133, GPS2-212-
327) require optimized plasmids for expression in E. coli. It is hypothesized that non-
endogenous proteins larger than 25 kDa will require optimization and that optimization 
will provide successful quantities of GPS2 require for binding assays. For the further goal 
of this project - the determination of the binding site of UBC13 and GPS2 - it is 
hypothesized that one of the two GG sites on GPS2’s sequence may be important in 
binding to UBC13, thereby competitively inhibiting ubiquitination activity. These are 
amino acids 136 and 137 and 185 and 186 respectively. Thus, we attempted to purify the 
entire GPS2 protein, the GPS2 fragment containing amino acids from 1-137 (GPS2-1st 
GG) as well as the fragment containing amino acids from 1-186 (GPS2-2nd GG).  Also, to 
confirm previous findings and have positive controls for binding experiments, fragments 
from the 1st 99 amino acids (to determine N-terminal sufficiency), from the last 212-327 
(to determine C-terminal sufficiency), as well as GPS2 1-133 and GPS2 1-212 were 
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purified. It was then determined which proteins required optimization and which did not. 
We expect that the full length GPS2 would be purified only in low quantities.  
 
Purifications of GST-tagged full length GPS2 and fragments: 
Initial purifications of GPS2 included all of the wild type sequence fragments and 
wild type full length formats of GPS2. These were plasmids CVP 257-CVP 361 shown in 
table 1. Each plasmid used for purification was tagged with GST. Protein purification 
results were deemed successful when bands of sizes corresponding to the known size of 
the respective protein were observed in gel electrophoresis or Western Blot results. GPS2 
fragment AA 2-99 and 2-133 were all purified successfully (Figure 2). Fragments ending 
at the first GG and second GG were purified with conflicting results in protein size 
(Figure 3). The conflicting results showed GPS2-1st GG as 47 kDa and GPS2-2nd GG as 
42 kDa.  
As expected, the full-length wild type GPS2 could not be purified satisfactorily. 
As the mutant variations of GPS2 are the same size as the wild type, it was concluded 
without purification that the expression of GPS2 full length mutant variations would not 
be able to be purified without optimization. Thus, fragments ending at the first GG and 
second GG as well as the full-length wild type and mutants were considered unable to be 
purified satisfactorily with their original mammalian sequences.  
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Plasmid Full length/Fragment Type Protein Size Purification Results 
CVP 258 Myc-UBC13 ~41 kDa -­‐    
CVP 263
  
HA-Flag-GPS2 ~45 kDa -­‐    
CVP 266 Flag-GPS2 1-212 ~ kDa -­‐    
CVP 292 GST-GPS2 (wild-type) ~64 kDa Unable to be 
purified 
CVP 346 GST-GPS2 with 1st GG mutation ~64 kDa Unable to be 
purified 
CVP 347 GST-GPS2 with 2nd GG mutation ~64 kDa Unable to be 
purified 
CVP 349 GST-GPS2 fragment 1-1st GG 
(AAs 1-137) 
~42 kDa  Purified with poor 
results 
CVP 358 GST- GPS2 fragment (AAs 1-99) ~38 kDa  Purified with 
original sequence 
CVP 359 GST-GPS2 fragment 1-2nd GG 
(AAs 1-186) 
~47 kDa  Purified with poor 
results 
CVP 360 GST-GPS2 fragment (AAs 212-
327) 
~39.7 kDa  Purified with 
original sequence 
CVP 361 GST-GPS2 fragment (AAs 1-133) ~44 kDa  Purified with 
original sequence 
CVP 451 GST-GPS2 (optimized sequence) ~64 kDa Purified (low yield) 
CVP 452 GST-GPS2 fragment 1st GG 
(optimized sequence, AAs 1-186) 
~42 kDa  Purified 
w/optimized 
sequence 
CVP 453 GST-GPS2 fragment 2nd GG 
(optimized sequence, AAs 1-186) 
~47 kDa  Purified 
w/optimized 
sequence 
CVP 454 GST-GPS2 with 1st GG mutation ~64 kDa To be purified 
before binding 
assay 
CVP 455 GST-GPS2 with 2nd GG mutation ~64 kDa To be purified 
before binding 
assay 
CVP 456 GST-GPS2 with 1st GG and 2nd GG 
mutation 
~64 kDa To be purified 
before binding 
assay 
Table 1: Plasmids Used 
 
21  
 
Figure 2: GPS2 1-99 Purification with Plasmid CVP 358 and GPS2 1-133 
Purification with Plasmid CVP 361 
Lanes left to right: ladder, whole cell lysis of GPS2 1-99, elution of GPS2 1-133 
(38kDa), whole cell lysis of GPS2 1-133, elution of GPS2 1-133 (44kDa), overflow of 
elution of GPS2 1-133  
 
 
Figure 3: Fragments GPS2-1st GG Purification with Plasmid CVP 349 and GPS2-2nd 
GG Purification with Plasmid CVP 359  
Lanes left to right: ladder, whole cell lysis, flow through, and elution of CVP 349 (42 
kDa), whole cell lysis, flow through, and elution of CVP 359 (47 kDa) 
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PCR Construction of Optimized Plasmids: 
 
Based on the wild type sequences of gps2 construct, we cannot purify target 
proteins from E. coli. One possible reason is the sequence of gps2 is from the mammalian 
gene, which is difficult to express in bacteria (Khow O. et al, 2012). Optimized sequences 
were made for the first GG and second GG fragment as well as the full length and first 
GG and second GG mutations. In order to obtain optimized sequences, the Invitrogen 
Geneart Synthesis database by Thermo Fisher was used to translate eukaryotic protein 
sequence to an optimized prokaryotic protein sequence. Primers and template DNA for 
PCR were obtained from Macrogen. Final PCR product sequences were also sent to 
Macrogen for verification by Sanger sequencing. 
In order to construct plasmids for the first GG and second GG fragment as well as 
the full length and first GG and second GG mutations, optimized sequences were 
formulated and sent to Macrogen for construction of PCR primers and templates. Typical 
PCR protocol was performed to create the first GG and second GG fragment as well as 
all full length gps2 plasmids. Results yielded the correct construction and sizes of each 
plasmid. 
The optimized gps2 construct was used as template DNA. The forward primer 
sequence was 5’ CGGGATCCCCTGCACTGCTGGAACGT 3’and the reverse primer 
sequence was 5’ CGGAATICACCACCAGGGCTACCC 3’. First, the target sequences 
was amplified by PCR. The PCR product and a pGEX vector containing a GST tag was 
then digested with compatible restriction enzymes BamH1 and EcoR1. The digestion 
reaction was successful as accurate DNA fragment sizes were observed for the vector and 
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each plasmid (Figures 5 and 6). The digested products were then cleaned by gel 
electrophoresis followed by the Qiagen PCR clean-up kit. The cleaned digested products 
were then ligated with T4 ligase buffer and T4 ligase. The solution was placed at 16°C 
overnight to ligate with the pGEX vector. Approximately 12 hours later, the ligation 
product was transformed into general, competent E. coli cells. Transformants were grown 
overnight at 37 °C on LB agar plates supplemented with ampicillin. In order to verify the 
correct PCR products were obtained and correctly oriented in the E. coli plasmids, 
colonies deemed correct were transferred to separate PCR tubes containing a ten-
microliter ready-made PCR solution with two microliters of each 5′ and 3′ sequencing 
primers added. PCR product was analyzed again – ten microliters each - by agarose gel 
electrophoresis. For each trial, two to three colonies were sent to Macrogen for screening 
in order to verify that the insert is in the proper orientation and in the correct reading 
frame. Figure 6 below shows the optimized gps2 sequence for primer creation and PCR 
plasmid creation. 
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Figure 4: Codon Optimization of Gps2 sequences  
Top: Optimized Sequence, Bottom: Original Sequence 
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Figure 5: Optimized Gps2 and pGEX JDK Vector Digest Test 
Lanes from left to right: ladder, pGEX vector, pGEX vector (5000 bp) and Gps2 
(900bp) 
 
 
 
Figure 6: Gps2, Gps2-1stGG, Gps2-2nd GG PCR Test  
Lanes 1 and 2, ladder, lane 1, Gps2-1st GG (411 bp), lane 2 Gps2-2nd GG (558 bp), 
lane 3 Gps2 (900 bp) 
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Purifications of GPS2 with Optimized Sequences: 
 
Optimized sequences were made for the first GG and second GG fragment as well 
as the full length and first GG and second GG mutations. Purification results for 
optimized sequences were successful with results varying from high (expressed with 
clear bands on gel electrophoresis) to low yield (bands only confirmed using sensitive 
techniques such as western blot and silver staining of gel electrophoresis). Plasmids with 
optimized sequences include CVP 451-CVP 456 shown in table 1.  
Low yield purification results were further verified for successful protein 
purification with Western Blot and silver staining, which are more sensitive testing 
methods to indicate presence of protein purification. These methods are capable of 
verifying protein expression at levels as low as one nanogram. Three plasmids, CVP 258, 
CVP 263, and CVP 266 were not used for the purposes of protein purification but for the 
purposes of TnT Quick Coupled Transcription/Translation in preparation for binding 
assays. In order to construct plasmids for the first GG and second GG fragment as well as 
the full length and first GG and second GG mutations, optimized sequences were 
formulated and sent to Macrogen for construction of PCR primers and templates. Typical 
PCR protocol was performed to create the first GG and second GG fragment as well as 
all full length GPS2 plasmids. Results yielded the correct construction and sizes of each 
plasmid. 
After transformation of constructed plasmids into BL21 E. coli was performed 
and cultures plated, purifications on plasmids CVP 45, CVP 452, and CVP 453 were 
performed. Results showed 1st GG and 2nd GG fragments purified with expected yield 
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(50+ ng) on gel electrophoresis without sensitive staining techniques. Two trials of the 
fragments were performed because initial results showed very close bands between 
42kDa and 47kDa for GPS2 1st GG and GPS2 2nd GG respectively (Figures 7 and 8). Full 
length GPS2 purification showed low yield (~1+ng) and required Western Blotting and 
silver staining of gels (Figures 9 and 10). Purification results of CVP452 and CVP 453 
confirmed the hypothesis that optimized sequences would yield results high enough for 
viewing on gel electrophoresis. However, purifications of CVP451 showed purification 
results well below 50ng as expression levels were unable to be seen without silver 
staining or Western Blotting. High, low and zero yield results are show below (Figures 7 
-10).  
 
 
Figure 7: Optimized GPS2-1st GG and GPS2-2nd GG Purifications  
Lanes left to right: ladder, whole cell lysis, flow through, and elution of CVP 452 (42 
kDa)  (lanes 3 and 4); whole cell lysis, flow through, and elution of CVP 453 (47 
kDa) (lanes 7, 8, 9) 
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Figure 8: Optimized Fragments GPS2-1st GG, GPS2-2nd GG, and Optimized GPS2 
Full-Length Purifications  
Lanes left to right: whole cell lysis, flow through, and elution of CVP 452 (42 kDa), 
whole cell lysis, flow through, and elution of CVP 453 (47 kDa), and whole cell lysis, 
flow through, and elution of CVP 451 (64 kDa) 
 
 
 
Figure 9: Optimized GPS2 Western Blot with Plasmid CVP 451 
Lanes left to right: ladder, whole cell lysis, flow through, elution (64 kDa) 
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Figure 10: Optimized Full-Length GPS2 Purification with Silver Stain (500mL Flow 
Through; 100uL GST Beads) 
Lanes left to right: ladder, whole cell lysis, flow through, elution, elution (64 kDa) 
 
 
Mutagenesis Results: 
 
The Site-Directed Mutagenesis Kit from Agilent Technologies was used to create 
mutations for the 1st GG, 2nd GG, and double mutation of the full length GPS2. Typical 
PCR construction was then followed. Sequences were also sent to Macrogen for 
verification. Two complimentary oligonucleotide primers containing the desired mutation 
were ordered from Macrogen. For the 1st GG mutation primers, the forward primer was 5’ 
–GCATGCAGGGTAGCCCTGCAGCCCATAATCGTCCGGGTAC – 3’.  The reverse 
primer for the 1st GG mutation was 5’– GTACCCGGACGATTATGGGCTGCAGGGCT 
ACCCTGCATGC – 3’. The forward primer for the 2nd GG mutation was 5’ – GGTGCC 
ATAGGCAGCCGCAGGTGAACCCTGAAACTG  – 3’ while the reverse primer was 5’ 
– CAGTTTCAGGGTTCACCTGCGGCTGCCTATGGCACC– 3’. These primers were 
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used with the wild type GPS2 DNA template. For the double mutation, the 2nd GG 
mutation DNA plasmid template was used and the 1st GG forward and reverse primers 
were used. For plasmid creation, primers were diluted with distilled water to 100uM. 
Primers were then diluted to ten micromolar concentration in 1.5mL tubes in preparation 
for individual PCR reaction experiments. Four PCR vials of PCR reaction formula were 
made to contain fifty microliters total. Verification from Macrogen showed successful 
plasmid construction for each mutation type. These plasmids were then transferred to 
BL21 E. coli cells in preparation for purification after initial binding assay results. 
 
TnT and Binding Assay Results: 
As we already have all types of purified gps2, next we need to express another 
factor for in-vitro binding. TnT protocol was followed to construct UBC13 with Myc 
tagging for a binding assay with GPS2 GST tagging. TnT results were analyzed by 
Western Blot analysis. Results were deemed successful when the appropriate band size 
(~18 kDa) appeared on Western Blot (Figure 11). TnT results showed UBC13 had been 
successfully transcribed and translated by the TnT process. After obtaining UBC13 
protein in TnT solution, an in vitro binding assay between GPS2 and the UBC13 TnT 
product was performed as a positive control as it is known that GPS2 and UBC13 bind in 
vivo. Positive results for the binding assay between UBC13 and GPS2 were unable to be 
attained (Figure 12). 
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Figure 11: UBC13 TnT Results 
Lane 1: Ladder, Lane 2: UBC13-TnT (18 kDa) 
 
 
Figure 12: In-Vitro Binding Assay Results UBC13 (TnT) and Optimized Full-Length 
GPS2 (purified) 
Lanes left to right: ladder, input 1, input 2, ladder, elution 1, elution 2, elution 3. 
Elution 1: 5ul TnT+5ul beads, Elution 2: 10ul TnT+5ul beads, Elution 3: 20ul 
TnT+5ul beads 
No corresponding 
band sizes present 
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DISCUSSION 
 
GPS2 has been identified as an important protein in both genomic and non-
genomic functions by means of the inhibition of K63 ubiquitination. Through inhibiting 
UBC13, important pathways associated with the regulation of insulin, tumor suppression, 
and inflammation are affected. Recent studies have confirmed that GPS2 is an inhibitor 
of the UBC13/TRAF2/TRAF6 activated pro-inflammatory pathways, and UBC13 
activated AKT pathways associated with insulin regulation (Bi H. et al., 2014; Fan R. et 
al., 2016). Accordingly, GPS2 could possibly be an important site of interest due to its 
downstream effects on metabolic and inflammatory pathways that influence obesity and 
various cancers. In this study, we set out to dissect the UBC13-GPS2 binding in order to 
determine the localization of GPS2 minimal interaction domain required for binding and 
inhibition of UBC13. The goal of my project was to perform protein expression and 
purifications from E. Coli for performing in vitro binding assays. 
The first thing I accomplished was to optimize the constructs required for GPS2 
expression. While investigating which forms and protein fragments of GPS2 can be 
purified in quantities high enough to be detected and used for in-vitro binding assay, we 
discovered that full length GPS2 proteins and protein fragments larger than 25 
kilodaltons in length were difficult to express and required optimization for successful E. 
coli protein expression (Table 1). We conclude that, due to there not being a 
corresponding endogenous GPS2 protein in E. coli, the bacteria has difficulty expressing 
this protein and its protein fragments.  
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I constructed optimized plasmid sequences based on an optimized codon attained 
from the Invitrogen Geneart Synthesis database by Thermo Fisher. GPS2-1st GG and 
GPS2-2nd GG were then successfully purified with their optimized sequences. 
Unfortunately, the full-length version of GPS2 only ever achieved minimal – 
approximately 1-10 ng – purification results (Figure 10; Figure 11-14; Table 1). This, we 
conclude, is due to the fact that GPS2 is not endogenous to E. coli. When tasked with 
expressing non-endogenous gene products, E. coli often makes misfolded proteins 
(Lesley S. et. al, 2002). A common response to the cellular stress of accumulating 
misfolded proteins is a molecular switch from production of the misfolded protein to 
induction of protein pathways meant to deal with the translational stress of misfolded 
proteins (Lesley S. et. al, 2002). This likely affected the levels of protein expression in 
the present study. 
In the process of determining the GPS2-UBC13 binding site with in-vitro binding 
assay, we were only able to get positive UBC13 expression after one TnT Quick Coupled 
Transcription/Translation trial. Further, we were unable to confirm binding in our 
positive binding control between the full length optimized GPS2 and UBC13. This, we 
conclude, is also a result of improper folding of GPS2 into its secondary protein structure. 
Because secondary and tertiary protein structure can be crucial to protein interaction, the 
incorrect or lack of folding of GPS2 may seriously inhibit its ability to bind to UBC13. 
As a result, showing the positive control binding results with full length GPS2 and 
UBC13 was likely affected by both minimal GPS2 protein expression and incorrect 
folding. Accordingly, binding assays could not be performed with GPS2 plasmids with 
34  
mutations at its 1st GG, GPS2 with mutations at its 2nd GG, and GPS2 with mutations at 
both GG sites in order to further test the importance of the GG sites to GPS2-UBC13 
binding. Further work on this study requires investigation on how to optimize large 
endogenous protein expression and proper protein folding in E. coli.  
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